Low Asialoglycoprotein Receptor Expression As Markers for Highly Proliferative Potential Hepatocytes
Overview
Authors
Affiliations
Development of a reliable method to isolate highly proliferative potential hepatocytes will provide insight into the molecular mechanisms of liver regeneration, as well as proving crucial for the development of a biohybrid artificial liver. The aim of this study is to isolate highly proliferative, e.g., progenitor-like, hepatocytes. To this end, we fractionated hepatocytes expressing low and high levels of the asialoglycoprotein receptor (ASGP-R) based on the difference in their adhesion to poly[N-p-vinylbenzyl-O-beta-d-galactopyranosyl-(1-->4)-d-gluconamide] (PVLA), and examined the proliferative activity and gene expression of these fractionated hepatocytes. The results showed that approximately 0.5 to 1% of the total number of hepatocytes, which showed low adhesion to PVLA, expressed low levels of the ASGP-R, while the rest of hepatocyte population with high adhesion to PVLA expressed high levels of the ASGP-R. Interestingly hepatocytes with low ASGP-R expression levels had much higher DNA synthesizing activity (i.e., are much more proliferative) than those with high ASGP-R expression levels. Moreover, hepatocytes with low ASGP-R expression levels expressed higher levels of epidermal growth factor receptor (EGF-R), CD29 (beta1 integrin) and CD49f (alpha6 integrin) and lower levels of glutamine synthetase than those with high ASGP-R expression. These findings suggested that hepatocytes with low adhesion to PVLA due to their low ASGP-R expression could be potential candidates for progenitor-like hepatocytes due to their high proliferative capacity; hence, the low expression of the ASGP-R could be a unique marker for progenitor hepatocytes. The isolation of hepatocytes with different functional phenotypes using PVLA may provide a new research tool for a better understanding of the biology of hepatocytes and the mechanisms regulating their proliferation and differentiation in health and disease.
Meng Q, Tao C, Qiu Z, Akaike T, Cui F, Wang X Int J Nanomedicine. 2015; 10:2313-23.
PMID: 25848252 PMC: 4376262. DOI: 10.2147/IJN.S75011.
Efficient hepatic delivery of drugs: novel strategies and their significance.
Mishra N, Yadav N, Rai V, Sinha P, Yadav K, Jain S Biomed Res Int. 2013; 2013:382184.
PMID: 24286077 PMC: 3826320. DOI: 10.1155/2013/382184.
Kryczka J, Stasiak M, Dziki L, Mik M, Dziki A, Cierniewski C J Biol Chem. 2012; 287(43):36556-66.
PMID: 22898815 PMC: 3476322. DOI: 10.1074/jbc.M112.384909.
Establishment of a human neonatal hepatocyte cell line.
Reid Y, Gaddipati J, Yadav D, Kantor J In Vitro Cell Dev Biol Anim. 2009; 45(9):535-42.
PMID: 19565302 DOI: 10.1007/s11626-009-9219-0.
Ise H, Nikaido T, Negishi N, Sugihara N, Suzuki F, Akaike T Am J Pathol. 2004; 165(2):501-10.
PMID: 15277224 PMC: 1618566. DOI: 10.1016/S0002-9440(10)63315-9.